CTYX Connectyx Technologies Holding

Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies
EN
09/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Connectyx Technologies Holding

 PRESS RELEASE

Curative Biotechnology Announces Reverse Stock Split and Strategic Pro...

Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced a reverse stock split (“Reverse Stock Split”) of its common stock at a ratio of 1-for-150. The Reverse Stock Split became effective at 12:00 a.m. Eastern Time on March 23, 2...

 PRESS RELEASE

Curative Biotechnology Announces Reverse Stock Split and Strategic Pro...

Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced a reverse stock split (“Reverse Stock Split”) of its common stock at a ratio of 1-for-150. The Reverse Stock Split became effective at 12:00 a.m. Eastern Time on March 23, 20...

 PRESS RELEASE

Curative Biotechnology Announces Canadian Patent Allowance

Curative Biotechnology Announces Canadian Patent Allowance “Druggable Target to Treat Retinal Degeneration” Palm Beach Gardens, FL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a company developing metformin-based eye drops for the treatment of degenerative eye diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for Canadian Patent Application No. 3,151,011, entitled “Druggable Target to Treat Retinal Degeneration.” Curative is the exclusive worldwide licensee of thi...

 PRESS RELEASE

Curative Biotechnology, Inc. Announces Letter to Shareholders

Curative Biotechnology, Inc. Announces Letter to Shareholders Strategic Update and New Path to Value Creation Palm Beach Gardens, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced the following update to shareholders. Dear fellow shareholders and interested investors, We are writing to provide an important update on our business strategy and operational path forward. The Company has been actively pursuing th...

 PRESS RELEASE

Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, In...

Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic Advisor Palm Beach Gardens, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced the engagement of Golden Eagle Capital Advisors, Inc (“GECA”), a financial advisory group based in Dubai as the exclusive agent and strategic advisor to the company. About Golden Eagle Capital Advisors, Inc. GOLDEN EAGLE CAPITAL...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch